Summary of Key Points Core Viewpoint - On October 17, 42 Hong Kong-listed companies conducted share buybacks, totaling 46.36 million shares and an aggregate amount of HKD 621 million [1][2]. Company-Specific Summaries - **Xiaomi Group-W**: - Repurchased 10.70 million shares for HKD 494 million, with a highest price of HKD 46.760 and a lowest price of HKD 45.900. The total buyback amount for the year reached HKD 1.537 billion [1][2]. - **Sihuan Pharmaceutical**: - Repurchased 15 million shares for HKD 21.76 million, with a highest price of HKD 1.470 and a lowest price of HKD 1.430. The total buyback amount for the year reached HKD 143.32 million [1][2]. - **Mengniu Dairy**: - Repurchased 1.20 million shares for HKD 16.97 million, with a highest price of HKD 14.250 and a lowest price of HKD 14.070. The total buyback amount for the year reached HKD 433.54 million [1][2]. - **AAC Technologies**: - Repurchased 300,000 shares for HKD 11.60 million, with a highest price of HKD 38.800 and a lowest price of HKD 38.480. The total buyback amount for the year reached HKD 84.64 million [1][2]. - **Vitasoy International**: - Repurchased 1.02 million shares for HKD 8.20 million, with a highest price of HKD 8.040 and a lowest price of HKD 8.020. The total buyback amount for the year reached HKD 27.54 million [1][2]. Overall Market Activity - The highest buyback amount on October 17 was from Xiaomi Group-W at HKD 494 million, followed by Sihuan Pharmaceutical at HKD 21.76 million. Other notable companies included Mengniu Dairy and AAC Technologies [1][2]. - In terms of share quantity, Sihuan Pharmaceutical led with 15 million shares repurchased, followed by Xiaomi Group-W with 10.70 million shares and Anton Oilfield Services with 4.49 million shares [1][2].

Core Viewpoint - Multiple companies in China conducted share buybacks on October 17, 2025, with Xiaomi Group-W leading in terms of buyback amount and quantity [1][2] Group 1: Buyback Details - Xiaomi Group-W (01810) repurchased 10.70 million shares for a total of 494 million yuan, with a year-to-date total of 27.30 million shares, representing 0.110% of its total share capital [2] - Four Seasons Pharmaceutical (00460) repurchased 15 million shares for 21.76 million yuan, with a year-to-date total of 59.60 million shares, representing 0.647% of its total share capital [2] - Mengniu Dairy (02319) repurchased 1.20 million shares for 16.97 million yuan, with a year-to-date total of 18.52 million shares, representing 0.473% of its total share capital [2] Group 2: Other Notable Buybacks - VITASOY International (00345) repurchased 1.02 million shares for 8.20 million yuan, with a year-to-date total of 566.60 million shares, representing 0.540% of its total share capital [2] - Zhongtong Express-W (02057) repurchased 445,000 shares for 8.41 million yuan, with a year-to-date total of 5.07 million shares, representing 0.630% of its total share capital [2] - Huazhong Media (00685) repurchased 500,000 shares for 50,000 yuan, with a year-to-date total of 225.60 million shares, representing 0.139% of its total share capital [2]

Core Insights - The completion of subject enrollment for the Phase IIa study of ASC30, a small molecule GLP-1 receptor agonist for obesity treatment, marks a significant milestone in its development [1][2] - ASC30 is designed as a depot formulation for subcutaneous administration once a month, with a 12-week duration study involving 65 participants [1] - The observed half-life of ASC30 is 46 days, supporting its monthly dosing regimen, while the terminal half-life is 36 days [1][2] Group 1: Study Details - The Phase IIa study is randomized, double-blind, placebo-controlled, and multi-center, aimed at assessing safety, tolerability, and efficacy in obese subjects with a BMI of ≥30 kg/m² or overweight subjects with at least one weight-related comorbidity [1] - The study is divided into three cohorts with different dosages, and top-line data is expected in Q1 2026 [1] Group 2: Drug Characteristics - ASC30 has a peak-to-trough ratio of approximately 1.5:1, indicating its pharmacokinetic profile [2] - The drug is developed using the company's proprietary Ultra Long-Acting Platform (ULAP), which overcomes limitations of albumin-dependent half-life extension technologies [2] - ASC30 is the first and only small molecule GLP-1R agonist that can be administered both orally and via subcutaneous injection, suitable for both weight loss and weight maintenance therapies [3] Group 3: Intellectual Property - ASC30 is a new chemical entity (NCE) with patent protection in the U.S. and globally, valid until 2044 without considering patent extensions [3]

Core Viewpoint - The completion of subject enrollment in the Phase IIa study of ASC30, a small molecule GLP-1 receptor agonist for obesity treatment, marks a significant milestone in the development of this innovative therapy [1][2]. Group 1: Study Details - The Phase IIa study is a 12-week, randomized, double-blind, placebo-controlled, multi-center clinical trial conducted in the U.S. with 65 participants, all of whom are either obese or overweight with at least one weight-related comorbidity [1]. - The study aims to evaluate the safety, tolerability, and efficacy of ASC30 in subjects with a body mass index (BMI) of ≥ 30 kg/m² or those with a BMI between 27 kg/m² and 30 kg/m² [1]. - Top-line data from the study is expected in the first quarter of 2026 [1]. Group 2: Pharmacokinetics and Technology - The observed half-life of ASC30 in obese subjects is 46 days, supporting a once-monthly dosing regimen, while the terminal half-life is 36 days [1]. - The peak-to-trough ratio of the drug is approximately 1.5:1, indicating favorable pharmacokinetic properties [2]. - ASC30 is developed using the company's proprietary ultra-long-acting drug development platform (ULAP), which overcomes limitations of albumin-dependent half-life extension technologies [2]. Group 3: Product Characteristics - ASC30 is the first and only small molecule GLP-1 receptor agonist that can be administered both orally and via subcutaneous injection, suitable for both weight loss treatment and maintenance [2][3]. - The compound is a new chemical entity (NCE) with patent protection in the U.S. and globally until 2044, excluding any patent extensions [3].

Core Viewpoint - The completion of subject enrollment in the Phase IIa study for ASC30, a novel GLP-1 receptor agonist for obesity treatment, marks a significant milestone in the development of this innovative therapy [1] Company Summary - Songlei Pharmaceutical-B (01672.HK) has announced the completion of subject enrollment for its monthly subcutaneous depot formulation of the small molecule GLP-1 receptor agonist ASC30 in the United States [1] - The study involved 65 participants, all of whom are either obese or overweight individuals with at least one weight-related comorbidity [1] - The CEO of Songlei, Dr. Wu Jinzi, highlighted the importance of this milestone, indicating substantial progress in the development of ASC30 [1] Product Summary - ASC30 is the first and only small molecule GLP-1 receptor agonist that can be administered either orally once daily or via subcutaneous injection once a month to once a quarter [1] - The product is designed for both weight loss treatment and weight maintenance therapy, aimed at long-term weight management [1] - ASC30 features a prolonged apparent half-life of 46 days and a superior peak-to-trough ratio of approximately 1.5, positioning it as a promising monthly treatment option for obesity [1] - Topline data from the Phase IIa study is expected to be available in the first quarter of 2026 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Ascletis Pharma Inc. 歌禮製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1672） 自願性公告 歌禮完成小分子GLP-1R激動劑ASC30治療肥胖症的 每月一次皮下儲庫型治療製劑的美國IIa期研究受試者入組 本公告乃歌禮製藥有限公司（「本公司」或「歌禮」，連同其附屬公司稱為「本集 團」）自願作出，以使本公司股東及潛在投資者了解本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）宣佈，其小分子GLP-1受體(GLP-1R)激動劑 ASC30治療肥胖症的每月一次皮下儲庫型(depot)製劑（治療製劑）的美國IIa期研究 (NCT06679959)已於近期完成受試者入組。65例受試者均為肥胖人群或伴有至少 一種體重相關合併症的超重人群。 ASC30每月一次皮下儲庫型治療製劑的IIa期研究是一項在美國開展的、為期 12周、隨機、雙盲、安慰劑對照及多中心的臨床研究，旨在 ...

Core Viewpoint - The company, Gilead Sciences-B (01672.HK), announced a share buyback on October 17, 2023, spending HKD 915,000 to repurchase 100,000 shares [1] Summary by Category Company Actions - Gilead Sciences-B executed a buyback of 100,000 shares at a cost of HKD 915,000 on October 17, 2023 [1]

Group 1 - Company Gilead Sciences-B (01672) announced a share buyback of 100,000 shares at a cost of HKD 915,250 on October 17, 2025 [1]

Core Viewpoint - Company Gilead Sciences-B (01672) announced a share buyback of 100,000 shares at a cost of HKD 915,250 on October 17, 2025 [1] Summary by Category - **Company Actions** - Gilead Sciences-B plans to repurchase 100,000 shares [1] - The total expenditure for the buyback is HKD 915,250 [1]

| 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01672 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年10月15日 | 992,874,320 | | 6,084,210 | | 998,958,530 | | 1). 購回股份 (股份被持作庫存股份) | | | -100,000 0.0101 % | 100,000 HKD | 9.1525 | | | 變動日期 | 2025年10月17日 | | | | | | | 於下 ...